Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology Consensus approach Clinical Neurology 610 tau Proteins cerebrospinal fluid [Amyloid beta-Peptides] DIAGNOSIS RECOMMENDATIONS Cerebrospinal fluid biomarkers Alzheimer Disease 616 CRITERIA Humans ddc:610 cerebrospinal fluid [Peptide Fragments] clinical report cerebrospinal fluid biomarkers consensus approach Science & Technology Amyloid beta-Peptides Featured Articles 9. Industry and infrastructure [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology diagnosis [Alzheimer Disease] Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience Alzheimer's disease 16. Peace & justice Clinical report Peptide Fragments 3. Good health cerebrospinal fluid [Alzheimer Disease] Alzheimer's disease; cerebrospinal fluid biomarkers; clinical report; consensus approach; harmonization cerebrospinal fluid [Biomarkers] cerebrospinal fluid [tau Proteins] Harmonization harmonization Neurosciences & Neurology Human medicine Life Sciences & Biomedicine Alzheimer’s disease Biomarkers
DOI: 10.1002/alz.12545 Publication Date: 2021-12-22T12:18:10Z
ABSTRACT
AbstractIntroductionThe current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.MethodsWe obtained a description of (pre‐)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.ResultsThe (pre‐)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DiscussionThis is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (37)